HemaCare Signs Distribution Agreement With China-Based Partner
LOS ANGELES – [May 12, 2016] – HemaCare Corporation, (OTCBB: HEMA) a leader in cell and tissue collection, processing, and cell therapy solutions, has expanded its global capabilities through a strategic distribution agreement in China with Shanghai-based MT-Biological Science and Technology Co. Ltd. This partnership ensures researchers in China can access HemaCare’s human healthy and disease state cryopreserved hematopoietic cell products for their basic scientific and cell therapy research and development needs in a timely manner and with local region support.
HemaCare distribution agreements enable partners to actively provide support to customers. A complete overview of these distribution partners can be found at www.hemacare.com/distributors. Researchers are able to obtain both fresh and cryopreserved cells through direct shipments from HemaCare’s FDA-registered donor collection center, as well as its cell isolation laboratory in California, while receiving customer service and technical support in their native language through specially trained representatives locally in their region. HemaCare also provides ongoing technical training and marketing support to assist global partners in providing best in class service and support.
According to Pete van der Wal, HemaCare’s Chief Executive Officer, HemaCare’s partnership through these regional agreements demonstrates the company’s commitment to supporting the global research and development of cell therapies.
“Our cell and tissue collection expertise, registry of profiled, recallable donors, extensive capabilities in processing, cold chain logistics management, and professional consulting services makes HemaCare a partner of choice to support the unique needs and requirements of worldwide scientific and cell therapy researchers,” van der Wal said.